Loading company…
Pharming Group develops protein replacement therapies and precision medicines for rare diseases from Leiden, Netherlands.
Founded in 1988 in Leiden, Netherlands, Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines for rare diseases. Its flagship product, Ruconest, treats acute hereditary angioedema attacks. Sijmen De Vries is the CEO, and the company reported revenue of EUR 245.32 mn and EBITDA of EUR 10.54 mn for 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in